BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 21926964)

  • 1. Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.
    Deshpande A; Reddy MM; Schade GO; Ray A; Chowdary TK; Griffin JD; Sattler M
    Leukemia; 2012 Apr; 26(4):708-15. PubMed ID: 21926964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms.
    Takei H; Coelho-Silva JL; Tavares Leal C; Queiroz Arantes Rocha A; Mantello Bianco T; Welner RS; Mishima Y; Kobayashi IS; Mullally A; Lima K; Machado-Neto JA; Kobayashi SS; Lobo de Figueiredo-Pontes L
    Cancer Sci; 2022 Feb; 113(2):597-608. PubMed ID: 34808021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
    Hobbs GS; Rozelle S; Mullally A
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms.
    Mullally A
    Pathologe; 2016 Nov; 37(Suppl 2):175-179. PubMed ID: 27796499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
    Quintás-Cardama A; Vaddi K; Liu P; Manshouri T; Li J; Scherle PA; Caulder E; Wen X; Li Y; Waeltz P; Rupar M; Burn T; Lo Y; Kelley J; Covington M; Shepard S; Rodgers JD; Haley P; Kantarjian H; Fridman JS; Verstovsek S
    Blood; 2010 Apr; 115(15):3109-17. PubMed ID: 20130243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Not Available].
    Soret J; Kiladjian JJ
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S29-38. PubMed ID: 27494970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.
    de Melo Campos P; Machado-Neto JA; Eide CA; Savage SL; Scopim-Ribeiro R; da Silva Souza Duarte A; Favaro P; Lorand-Metze I; Costa FF; Tognon CE; Druker BJ; Olalla Saad ST; Traina F
    Oncotarget; 2016 Feb; 7(6):6948-59. PubMed ID: 26755644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.
    Bhagwat N; Levine RL; Koppikar P
    Int J Hematol; 2013 Jun; 97(6):695-702. PubMed ID: 23670175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New generation small-molecule inhibitors in myeloproliferative neoplasms.
    Passamonti F; Maffioli M; Caramazza D
    Curr Opin Hematol; 2012 Mar; 19(2):117-23. PubMed ID: 22227528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
    Bogani C; Bartalucci N; Martinelli S; Tozzi L; Guglielmelli P; Bosi A; Vannucchi AM;
    PLoS One; 2013; 8(1):e54826. PubMed ID: 23382981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK2 kinase inhibitors and myeloproliferative disorders.
    Chen AT; Prchal JT
    Curr Opin Hematol; 2010 Mar; 17(2):110-6. PubMed ID: 20087176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms.
    Bartalucci N; Tozzi L; Bogani C; Martinelli S; Rotunno G; Villeval JL; Vannucchi AM
    J Cell Mol Med; 2013 Nov; 17(11):1385-96. PubMed ID: 24237791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.
    Panani AD
    Cancer Lett; 2009 Oct; 284(1):7-14. PubMed ID: 19269737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy.
    Brkic S; Stivala S; Santopolo A; Szybinski J; Jungius S; Passweg JR; Tsakiris D; Dirnhofer S; Hutter G; Leonards K; Lischer HEL; Dettmer MS; Neel BG; Levine RL; Meyer SC
    Leukemia; 2021 Oct; 35(10):2875-2884. PubMed ID: 34480104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy with JAK2 inhibitors for myeloproliferative neoplasms.
    Santos FP; Verstovsek S
    Hematol Oncol Clin North Am; 2012 Oct; 26(5):1083-99. PubMed ID: 23009939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
    Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
    J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors.
    Helbig G
    Med Oncol; 2018 Aug; 35(9):119. PubMed ID: 30074114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms.
    Meyer SC
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):627-642. PubMed ID: 28673392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2 mutations and clinical practice in myeloproliferative neoplasms.
    Tefferi A
    Cancer J; 2007; 13(6):366-71. PubMed ID: 18032973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
    Pardanani A; Hood J; Lasho T; Levine RL; Martin MB; Noronha G; Finke C; Mak CC; Mesa R; Zhu H; Soll R; Gilliland DG; Tefferi A
    Leukemia; 2007 Aug; 21(8):1658-68. PubMed ID: 17541402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.